Ordering RecommendationRecommendations when to order or not order the test. May include related or preferred tests.
Use to assess for single gene mutations, including substitutions and smaller insertions and deletions, that may have prognostic and/or therapeutic significance in acute myeloid leukemia (AML).
MnemonicUnique test identifier.
AML NGS
MethodologyProcess(es) used to perform the test.
Massively Parallel Sequencing
PerformedDays of the week the test is performed.
Varies
ReportedExpected turnaround time for a result, beginning when ARUP has received the specimen.
12-14 days
New York DOH Approval StatusIndicates test has been approved by the New York State Department of Health.
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Specimen Required
Patient Preparation
Collect
Lavender (EDTA), Green (sodium heparin) Bone Marrow (EDTA) or Bone Marrow (sodium heparin), Fresh-frozen tissue.
Specimen Preparation
Whole Blood and Bone Marrow: Transport 3 mL whole blood. (Min: 1.5 mL) Fresh-frozen Tissue: Transport 5 mg fresh-frozen tissue. (Min: 5 mg) Separate specimens must be submitted when multiple tests are ordered
Storage/Transport Temperature
Whole Blood or Bone Marrow: Refrigerated. Fresh-frozen Tissue: Frozen.
Reference IntervalNormal range/expected value(s) for a specific disease state. May also include abnormal ranges.
By report
Interpretive DataBackground information for test. May include disease information, patient result explanation, recommendations, details of testing, associated diseases, explanation of possible patient results.
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Compliance Category
Laboratory Developed Test (LDT)
NoteAdditional information related to the test.
Genes tested: ANKRD26, ASXL1, CEBPA, DDX41, DNMT3A, ETV6, FLT3, GATA2, IDH1, IDH2, KIT, KRAS, NPM1*, NRAS, RUNX1, TP53, WT1 * One or more exons are not covered by sequencing for the indicated gene; see Additional Technical Information.
CPT CodesThe American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
AliasesOther names that describe the test. Synonyms.
Acute Myeloid Leukemia Mutation Panel by Next Generation Sequencing
Chat
Feedback
